[{"id":"e1f4b5d9-cd5a-47dd-995e-7ea37a995e84","acronym":"","url":"https://clinicaltrials.gov/study/NCT05464836","created_at":"2022-07-19T14:54:34.934Z","updated_at":"2024-07-02T16:35:19.865Z","phase":"Phase 2","brief_title":"Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL","source_id_and_acronym":"NCT05464836","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2 • CD8 • CD34 • CD5 • CD7 • CD2","pipe":"","alterations":" ","tags":["BCL2 • CD8 • CD34 • CD5 • CD7 • CD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • limantrafin (CB-103)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/06/2023","start_date":" 04/06/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-02-12"}]